NCT02864277

Brief Summary

The aim of this study is to compare outcomes of conventional perioperative care with those of an enhanced recovery after surgery (ERAS) perioperative care plan in women undergoing open abdominal surgery for gynecologic cancer or suspected gynecologic cancer. Investigators hypothesize that those patients randomized to the ERAS protocol will have shorter lengths of hospital stay, without increasing readmission rates. ASD

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
120

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Aug 2016

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

July 11, 2016

Completed
21 days until next milestone

Study Start

First participant enrolled

August 1, 2016

Completed
11 days until next milestone

First Posted

Study publicly available on registry

August 12, 2016

Completed
3.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2019

Completed
2 years until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2021

Completed
Last Updated

November 2, 2023

Status Verified

October 1, 2023

Enrollment Period

3.3 years

First QC Date

July 11, 2016

Last Update Submit

October 31, 2023

Conditions

Keywords

GynecologyCancerGeneral SurgeryRecovery QualityLength of hospital stay

Outcome Measures

Primary Outcomes (1)

  • Total length of hospital stay (days)

    total length of hospital stay (days)

    Up to 10 days

Secondary Outcomes (9)

  • Achievement of Postoperative Milestones

    30 days

  • Surgical complications

    30 days

  • Readmission rates

    2 week and 30 day

  • Time to adjuvant treatment

    60 days

  • 30-day mortality rates

    30 days

  • +4 more secondary outcomes

Study Arms (2)

No Intervention Conventional Strategy

NO INTERVENTION

Perioperative Anesthetic No Intervention Management: Conventional Strategy Group 4 pages of concise directions on how to take care of the participant.

ERAS Group

EXPERIMENTAL

ERAS (enhanced recovery after surgery)

Procedure: No Intervention Conventional StrategyProcedure: ERAS

Interventions

The Conventional Strategy Group description encompasses over 4 pages of concise directions on how to take care of the participant. This cannot be reduced to less than 1000 characters. Preoperative Management Interoperative Management Postoperative Management Post discharge

ERAS Group
ERASPROCEDURE

The ERAS Group description encompasses over 3 pages of concise directions on how to take care of the participant. This cannot be reduced to less than 1000 characters. Preoperative Management Interoperative Management Postoperative Management Post discharge

ERAS Group

Eligibility Criteria

Age18 Years - 70 Years
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Women between the ages of 18-70 years
  • Fluent in English language
  • Known or suspected diagnosis of gynecologic malignancy (including ovarian, endometrial, and cervical cancers)
  • Scheduled for elective laparotomy
  • Medically eligible for major surgical procedure

You may not qualify if:

  • Unable to mobilize independently preoperatively
  • The following populations will not be included in the study: adults unable to consent (such as the cognitively impaired), minors \< 18 years of age, pregnant women, and prisoners.
  • Emergency surgery

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Prentice Women's Hospital

Chicago, Illinois, 60611, United States

Location

Related Publications (8)

  • Tewari KS, Java JJ, Eskander RN, Monk BJ, Burger RA. Early initiation of chemotherapy following complete resection of advanced ovarian cancer associated with improved survival: NRG Oncology/Gynecologic Oncology Group study. Ann Oncol. 2016 Jan;27(1):114-21. doi: 10.1093/annonc/mdv500. Epub 2015 Oct 20.

    PMID: 26487588BACKGROUND
  • Kehlet H, Wilmore DW. Multimodal strategies to improve surgical outcome. Am J Surg. 2002 Jun;183(6):630-41. doi: 10.1016/s0002-9610(02)00866-8.

    PMID: 12095591BACKGROUND
  • Kehlet H, Wilmore DW. Evidence-based surgical care and the evolution of fast-track surgery. Ann Surg. 2008 Aug;248(2):189-98. doi: 10.1097/SLA.0b013e31817f2c1a.

    PMID: 18650627BACKGROUND
  • Greco M, Capretti G, Beretta L, Gemma M, Pecorelli N, Braga M. Enhanced recovery program in colorectal surgery: a meta-analysis of randomized controlled trials. World J Surg. 2014 Jun;38(6):1531-41. doi: 10.1007/s00268-013-2416-8.

    PMID: 24368573BACKGROUND
  • Lu D, Wang X, Shi G. Perioperative enhanced recovery programmes for gynaecological cancer patients. Cochrane Database Syst Rev. 2015 Mar 19;2015(3):CD008239. doi: 10.1002/14651858.CD008239.pub4.

    PMID: 25789452BACKGROUND
  • Nelson G, Kalogera E, Dowdy SC. Enhanced recovery pathways in gynecologic oncology. Gynecol Oncol. 2014 Dec;135(3):586-94. doi: 10.1016/j.ygyno.2014.10.006. Epub 2014 Oct 12.

    PMID: 25316179BACKGROUND
  • Wijk L, Franzen K, Ljungqvist O, Nilsson K. Implementing a structured Enhanced Recovery After Surgery (ERAS) protocol reduces length of stay after abdominal hysterectomy. Acta Obstet Gynecol Scand. 2014 Aug;93(8):749-56. doi: 10.1111/aogs.12423. Epub 2014 Jun 13.

    PMID: 24828471BACKGROUND
  • Chau JPC, Liu X, Lo SHS, Chien WT, Hui SK, Choi KC, Zhao J. Perioperative enhanced recovery programmes for women with gynaecological cancers. Cochrane Database Syst Rev. 2022 Mar 15;3(3):CD008239. doi: 10.1002/14651858.CD008239.pub5.

MeSH Terms

Conditions

Neoplasms

Study Officials

  • Shireen Ahmad, MD

    Northwestern University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 11, 2016

First Posted

August 12, 2016

Study Start

August 1, 2016

Primary Completion

December 1, 2019

Study Completion

December 1, 2021

Last Updated

November 2, 2023

Record last verified: 2023-10

Data Sharing

IPD Sharing
Will not share

Locations